Application Ser. No.: 10/500,015 Filing Date: June 23, 2004 Examiner: Owens, Amelia A.

Amendment Pursuant to 37 C.F.R. § 1.121

IN THE CLAIMS:

The claims set forth below with amendments as indicated will replace all prior versions and listing of claims in the application.

1. (currently amended) A compound in the form of an enantiomer or in the form of a mixture of enantiomers, having the formula (I)

$$\begin{array}{c}
\mathbb{R} \\
\mathbb{N}
\end{array}$$

in which R represents a halogen atom or a (C_3-C_6) cycloalkyl group or a phenyl group substituted by one or more groups chosen from a halogen atom, or a (C_1-C_6) alkyl, (C_1-C_6) alkoxy, nitro, amino, (C_1-C_3) dialkylamino, trifluoromethyl, trifluoromethoxy, cyano, hydroxy, acetyl or methylenedioxy group, or a piperidinyl, or morpholin-4-yl, or pyrrolidin-1-yl, or azetidin-1-yl, or azetidin-1-yl, or pyridinyl, or quinolinyl, or thienyl, or pyrazinyl, or furyl, or benzofuryl, or benzothienyl, or indolyl, or pyrimidinyl, or isoxazolyl, or phenoxazinyl, or phenoxathienyl, or dibenzothienyl, or dibenzofuryl, or pyrrolyl, or naphthyl group, where each of these groups may optionally be substituted by one or more groups chosen from halogen atoms, (C_1-C_6) alkyl, (C_1-C_6) alkoxy, trifluoromethoxy, trifluoromethyl, nitro, cyano, hydroxy, amino, (C_1-C_3) dialkylamino or (C_3-C_8) cycloalkylamino groups, and where, of the two carbon-carbon bonds represented by ----, one is a single bond and the other is either a single bond or a double bond, or a salt thereof; and with the exception of following compounds:

5 (2 bromopyridin 5 yl) 1 azabicyclo[2.3.1]octane;

5 (2 chloropyridin 5 yl) 1 azabicyclo[2.3.1]octane;

5 (2 fluoropyridin 5 yl) 1 azabicyclo[2.3.1]octane.

Application Ser. No.: 10/500,015 Filing Date: June 23, 2004

Examiner: Owens, Amelia A.

2. (currently amended) The compound according to Claim 1 wherein R either

represents a halogen atom or a phenyl group substituted by one or more groups chosen

from halogen atoms and (C₁-C₆)alkyl, (C₁-C₆)alkoxy, nitro, amino, trifluoromethyl,

cyano, hydroxy, acetyl or methylenedioxy groups, or represents a pyridinyl group or a

thienyl group or an indolyl group or a pyrimidinyl group optionally substituted by one or

more (C_1-C_6) alkoxy groups.

3. (previously presented) A method for the treatment of a disorder selected from the

group consisting of detrimental memory and attentional changes, Alzheimer's disease,

Parkinson's disease, Tourette's syndrome and withdrawal from tobacco, which comprises

administering to a patient in need of said treatment an effective amount of a compound

according to Claim 1.

4. (previously presented) Pharmaceutical composition which comprises a compound

according to Claim 1, together with an excipient.

5. (previously presented) A method for the treatment of a disorder selected from the

group consisting of detrimental memory and attentional changes, Alzheimer's disease,

Parkinson's disease, Tourette's syndrome and withdrawal from tobacco, which comprises

administering to a patient in need of said treatment an effective amount of a compound

according to Claim 2.

6. (original) Pharmaceutical composition which comprises a compound according to

Claim 2, together with an excipient.

7. (new) A compound selected from the group consisting of:

5-(6-bromo-pyridin-3-yl)-1-aza-bicyclo[3.2.1]oct-2-ene; and

5-(6-bromo-pyridin-3-yl)-1-aza-bicyclo[3.2.1]oct-3-ene; or a salt thereof.

Application Ser. No.: 10/500,015 Filing Date: June 23, 2004

Examiner: Owens, Amelia A.

8 (new) A pharmaceutical composition which comprises a compound according to

Claim 7, or a pharmaceutically acceptable salt thereof together with an excipient.

9. (new) A method for the treatment of a disorder selected from the group consisting of

detrimental memory and attentional changes, Alzheimer's disease, Parkinson's disease,

Tourette's syndrome and withdrawal from tobacco, which comprises administering to a

patient in need of said treatment an effective amount of a compound according to Claim

7.